» Articles » PMID: 9353268

Preferential Interaction of Sentrin with a Ubiquitin-conjugating Enzyme, Ubc9

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 1997 Nov 14
PMID 9353268
Citations 79
Authors
Affiliations
Soon will be listed here.
Abstract

Sentrin is a ubiquitin-like molecule that has been shown to interact with the death domains of Fas and tumor necrosis factor receptor 1 (TNFR1), PML, Rad51, Rad52, and RanGAP1. We have reported previously that sentrin can be conjugated to other proteins in a manner analogous to protein ubiquitination (Kamitani, T., Nguyen, H. P., and Yeh, E. T. H. (1997) J. Biol. Chem. 272, 14001-14004). Furthermore, the conserved C-terminal Gly-Gly residues are required for sentrinization to occur. To identify enzymes which play a role in sentrinization, the yeast two-hybrid system was used to screen a human placenta cDNA library using sentrin as bait. A strong positive interacting clone was found to contain a cDNA insert encoding the ubiquitin-conjugating enzyme, Ubc9. The interaction between sentrin and Ubc9 required the ubiquitin domain and the C-terminal Gly-Gly residues of sentrin. This interaction appears to be specific because sentrin could only interact weakly with UbcH5B, but could not interact with HHR6B, UbcH6 nor E2-EPF. In vitro translated sentrin could be precipitated by a GST-Ubc9 fusion protein, but not by glutathione S-transferase. A beta-mercaptoethanol-sensitive Ubc9-sentrin conjugate could also be identified in the in vitro binding assay. Substitution of the conserved cysteine residue of Ubc9 by serine abolished the formation of the Ubc9-sentrin conjugate. Taken together, Ubc9 is a strong candidate to be the key conjugating enzyme in the sentrinization pathway.

Citing Articles

Single-cell transcriptomics in MI identify Slc25a4 as a new modulator of mitochondrial malfunction and apoptosis-associated cardiomyocyte subcluster.

Zhou T, Pan J, Xu K, Yan C, Yuan J, Song H Sci Rep. 2024; 14(1):9274.

PMID: 38654053 PMC: 11039722. DOI: 10.1038/s41598-024-59975-8.


The SUMOylation and ubiquitination crosstalk in cancer.

Li K, Xia Y, He J, Wang J, Li J, Ye M J Cancer Res Clin Oncol. 2023; 149(17):16123-16146.

PMID: 37640846 DOI: 10.1007/s00432-023-05310-z.


SUMO control of centromere homeostasis.

van den Berg S, Jansen L Front Cell Dev Biol. 2023; 11:1193192.

PMID: 37181753 PMC: 10172491. DOI: 10.3389/fcell.2023.1193192.


Characterizing the differential distribution and targets of Sumo1 and Sumo2 in the mouse brain.

Suk T, Nguyen T, Fisk Z, Mitkovski M, Geertsma H, Parmasad J iScience. 2023; 26(4):106350.

PMID: 37009224 PMC: 10060683. DOI: 10.1016/j.isci.2023.106350.


Glioblastoma upregulates SUMOylation of hnRNP A2/B1 to eliminate the tumor suppressor miR-204-3p, accelerating angiogenesis under hypoxia.

Guo Q, Fan Y, Wang Q, Li B, Qiu W, Qi Y Cell Death Dis. 2023; 14(2):147.

PMID: 36810326 PMC: 9944918. DOI: 10.1038/s41419-023-05663-w.